Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01288911 · ClinicalTrials.gov registry record · Phase 2
A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer
A Phase 2 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 375
- Enrollment target
NCT01288911 is a Phase 2 study that has completed, run by Astellas Pharma. The registered enrollment target is 375 participants.
The verdict
NCT01288911, a Phase 2 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 375 participants
- Enrollment target
Study Summary
The purpose of this study was to determine the efficacy and safety of oral enzalutamide compared to bicalutamide in castrate men with metastatic prostate cancer who have progressed while on Luteinizing Hormone Receptor Hormone (LHRH) agonist/antagonist or after receiving a bilateral orchiectomy.
Interventions
- DRUG enzalutamide
- DRUG bicalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2011-03-22 |
| Est. Completion | 2017-11-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01288911
The ClinicalTrials.gov registry entry for NCT01288911 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 375 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which enzalutamide is the first listed.
NCT01288911 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01288911 about?
NCT01288911 is a clinical study titled "A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer". The purpose of this study was to determine the efficacy and safety of oral enzalutamide compared to bicalutamide in castrate men with metastatic prostate cancer who have progressed while on Luteinizing Hormone Receptor Hormone (LHRH) agonist/antagonist or after receiving a bilateral orchiectomy.
What is the current status of trial NCT01288911?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 375 participants. The study started on 2011-03-22. Estimated completion is 2017-11-08.
What interventions are being tested in trial NCT01288911?
The interventions under investigation include: enzalutamide (DRUG), bicalutamide (DRUG).
Who is sponsoring clinical trial NCT01288911?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.